Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

This study has been completed.

Study NCT00765830 Information provided by Novartis

First Received on October 2, 2008. Last Updated on January 2, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

Diabetes Mellitus

More general conditions related to this trial

Interventions listed in this trial

vildagliptin
Placebo

More general drug interventions related to this trial

Sponsors listed in this trial

Novartis